ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Trading Up 1.8% – Here’s Why

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was up 1.8% during mid-day trading on Thursday . The company traded as high as $53.88 and last traded at $53.80. Approximately 19,145 shares traded hands during trading, a decline of 48% from the average daily volume of 36,471 shares. The stock had previously closed at $52.83.

ALPS Medical Breakthroughs ETF Stock Performance

The stock’s 50-day moving average is $53.15 and its 200-day moving average is $51.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Exencial Wealth Advisors LLC grew its position in ALPS Medical Breakthroughs ETF by 3.2% in the fourth quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock worth $415,000 after acquiring an additional 248 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of ALPS Medical Breakthroughs ETF by 2.8% during the 4th quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock valued at $628,000 after purchasing an additional 330 shares in the last quarter. McGuire Investment Group LLC lifted its stake in shares of ALPS Medical Breakthroughs ETF by 5.9% in the 4th quarter. McGuire Investment Group LLC now owns 8,798 shares of the company’s stock valued at $451,000 after purchasing an additional 488 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at $26,000. Finally, Griffin Asset Management Inc. boosted its holdings in ALPS Medical Breakthroughs ETF by 1.9% in the fourth quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock worth $1,572,000 after purchasing an additional 564 shares in the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.